Oral Azacitidine in Patients With Myelodysplastic Syndrome
- 20 September 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27), 3091-3092
- https://doi.org/10.1200/jco.21.01126
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2021
- Iron overload in myelodysplastic syndromes (MDS)International Journal of Hematology, 2017
- Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)European Journal of Haematology, 2014